David A. Siegel Amicus Therapeutics, Inc. Transaction History
Two Sigma Advisers, LP
- $41.3 Billion
- Q3 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Amicus Therapeutics, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 59,976 shares of FOLD stock, worth $575,169. This represents 0.0% of its overall portfolio holdings.
Number of Shares
59,976
Previous 83,676
28.32%
Holding current value
$575,169
Previous $830,000
22.89%
% of portfolio
0.0%
Previous 0.0%
Shares
22 transactions
Others Institutions Holding FOLD
# of Institutions
313Shares Held
314MCall Options Held
516KPut Options Held
833K-
Vanguard Group Inc Valley Forge, PA28.8MShares$276 Million0.01% of portfolio
-
Perceptive Advisors LLC New York, NY28.1MShares$269 Million7.83% of portfolio
-
Black Rock Inc. New York, NY24.4MShares$234 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA24MShares$230 Million0.05% of portfolio
-
Avoro Capital Advisors LLC New York, NY23.2MShares$222 Million3.72% of portfolio
About AMICUS THERAPEUTICS, INC.
- Ticker FOLD
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 280,497,984
- Market Cap $2.69B
- Description
- Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant bas...